Why the IRA will drive up the country’s drug bill — not lower it

On the surface, the Inflation Reduction Act is designed to lower drug prices, but its impact on innovation incentives could produce a landscape of new medicines that are costlier for patients.

By John LaMattina • Nov. 14, 2022

3 ways pharma can weather a recession

If “winter is coming” in the form of a recession, pharmas can take advantage of an inherent resiliency by crushing these three fundamentals.

By Michael Gibney • Nov. 10, 2022

Explore the Trendline➔

Tech for Clinical Trials

Companies that utilize these emerging technologies wisely are likely to find an edge in the increasingly competitive drug development arena.

By PharmaVoice staff

Novo Nordisk’s quantum bet on ‘world changing’ computing

Behind the pharma giant’s plans to build the first quantum computer by 2034 to accelerate drug development.

By Taren Grom • Nov. 10, 2022

This plant-based gel stops bleeding in seconds — and might have potential in drug delivery

29-year-old biotech founder Joe Landolina is hoping to capitalize on major possibilities in the human health market through his startup Cresolin and just inked a research partnership with Walter Reed.

By Karissa Waddick • Nov. 9, 2022

Woman of the Week: 82VS’s Trier Bryant

Welcome to the Woman of the Week podcast, a weekly discussion that illuminates the unique stories of women leaders who are catalyzing change throughout the life sciences industry. You can check out all our podcast episodes here. Not every leader makes it their mission to go where the fire ...

By Taren Grom • Nov. 9, 2022

While CAR-T wait times remain ‘heartbreaking,’ researchers push for innovations that could help

Facing an unprecedented manufacturing bottleneck, a new coalition is aiming to create the next generation of CAR-T therapies.

By Michael Gibney • Nov. 8, 2022

Chasing that ‘Time magazine cover potential’

Rami Elghandour was already retired. Then CAR-T specialist Arcellx lured him back into the industry to try to change the world.

By Alexandra Pecci • Nov. 8, 2022

After numerous setbacks, here’s where the Huntington’s pipeline stands

A look at emerging treatments and where there’s hope for patients.

By Kelly Bilodeau • Nov. 7, 2022

Real world data: Understanding the scope of EHR and claims data

Using RWE alongside clinical trial data has the potential to streamline time-to-insight while generating a fuller and more patient-centric view of a given therapy’s efficacy.

Nov. 7, 2022

Acumen cruises into the fast lane with novel Alzheimer’s treatment

The company’s distinct amyloid-beta target, which just won a fast track designation, could give it an edge over the competition.

By Meagan Parrish • Nov. 3, 2022

Pharma execs on creating a better workplace culture

Top women execs speak to the leadership skills they are embracing as the industry adjusts to a new normal.

By Taren Grom • Oct. 28, 2022

Riches, rags, riches: Is Biogen the Cinderella of biotechs?

Biogen and Eisai's new Alzheimer's drug is wowing investigators, and it might help the companies get past previous failures.

By Michael Gibney • Oct. 27, 2022

The first company to use Nobel-winning click chemistry in humans is on a mission to transform oncology

Shasqi founder and CEO José Mejía Oneto on how the company’s approach could provide a more effective alternative to ADCs and other emerging cancer therapies.

By Karissa Waddick • Oct. 27, 2022

A longtime believer in mRNA, Strand Therapeutics’ co-founder is now pushing the tech to the next level

The company’s co-founder and head of R&D on how it’s using synthetic mRNA to create “smarter” therapies that could provide cures for cancer and more.

By Alexandra Pecci • Oct. 25, 2022

Beyond cancer: Scientists push CAR-T cell therapies into new frontiers

Why a ‘very exciting’ trial of the therapy in lupus patients could swing the door open to new studies in autoimmune diseases.

By Kelly Bilodeau • Oct. 24, 2022

What’s keeping pharma leaders up at night

C-suite execs in the life sciences share their late-night thoughts including innovation, patient access and market factors.

By Taren Grom • Oct. 21, 2022

How a company aimed at bringing the woolly mammoth back to life spun off a startup that could speed drug development

Colossal Biosciences announced the creation of Form Bio — and its “operating system for science” — in September.

By Alexandra Pecci • Oct. 20, 2022

5 impactful drug trial failures from the last year

Major recent trial flops and what they mean for companies, patients and the industry.

By Meagan Parrish • Oct. 19, 2022

A new class of drugs with ‘huge’ potential in the fight against challenging breast cancers

Drug developers have been making headway in treating the most difficult and deadly forms of breast cancer.

By Kelly Bilodeau • Oct. 18, 2022

Think your company could be on HHS’ drug price negotiation list? Here’s how to navigate next steps

Know what to expect from the CMS over the next few months as it implements the drug reforms laid out in the Inflation Reduction Act.

By Karissa Waddick • Oct. 18, 2022

The Novartis U.S. Foundation’s president on the ‘magical piece’ of its 10-year health equity plan

Dr. Patrice Matchaba discusses Novartis’ end-to-end approach to tackling systemic health disparities.

By Meagan Parrish • Oct. 17, 2022

BIO’s interim CEO and Alvotech’s new chief quality officer could spell big changes for biotech

What these life science organizations’ latest executive-level appointments mean for the industry.

By Karissa Waddick • Oct. 14, 2022

Coming out of stealth, RIGImmune aims to catch up with ever-mutating viruses

President Susan Sobolov discusses how the startup is building on the work of two powerhouse Yale scientists to advance candidates for viruses — and beyond.

By Kelly Bilodeau • Oct. 13, 2022

Robotic pills could open a world of possibilities for the biologics market

As the oral biologic market heats up, Rani Therapeutics is looking to dominate the field with its robotic pill for treatment of chronic conditions. 

By Karissa Waddick • Oct. 13, 2022

Where the CEO of ADC Therapeutics sees ‘huge potential’ in the tech beyond oncology

The “magic bullet” approach of ADCs has been a breakthrough in cancer care — but this excitement could be just the beginning.

By Meagan Parrish • Oct. 12, 2022